SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-24-018175
Filing Date
2024-04-25
Accepted
2024-04-25 16:16:00
Documents
20
Period of Report
2024-06-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A bcrx-20240425.htm   iXBRL DEF 14A 1222234
6 GRAPHIC bcrx-20240425_g1.jpg GRAPHIC 22227
7 GRAPHIC bcrx-20240425_g2.jpg GRAPHIC 127983
8 GRAPHIC bcrx-20240425_g3.jpg GRAPHIC 109513
9 GRAPHIC bcrx-20240425_g4.jpg GRAPHIC 118233
10 GRAPHIC bcrx-20240425_g5.jpg GRAPHIC 129533
11 GRAPHIC bcrx-20240425_g6.jpg GRAPHIC 96447
  Complete submission text file 0001628280-24-018175.txt   3346831

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcrx-20240425.xsd EX-101.SCH 2355
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcrx-20240425_def.xml EX-101.DEF 2391
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcrx-20240425_lab.xml EX-101.LAB 2738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcrx-20240425_pre.xml EX-101.PRE 1472
23 EXTRACTED XBRL INSTANCE DOCUMENT bcrx-20240425_htm.xml XML 99104
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-23186 | Film No.: 24876528
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)